BeiGene Pharmaceuticals (Guangzhou) Co. Ltd.

Main objectives: 1. To compare the progression-free survival (PFS) of patients with locally advanced non-small cell lung cancer (LA NSCLC) with PD-LI expression level ≥ 50% who have not progressed after concurrent chemoradiotherapy (cCRT) between group A (ospelizumab + tislelizumab) and group C (durvalumab), as assessed by an independent review committee (IRC) according to RECIST version 1.1; 2. To compare the PFS of patients with LA NSCLC who have not progressed after cCRT with PD-LI expression level ≥ 1% between group A (ospelizumab + tislelizumab) and group C (durvalumab), as assessed by IRC according to RECIST version 1.1.